Mastering 21 CFR Part 312: Navigating the Investigational New Drug Application Process and Beyond

In today’s dynamic regulatory landscape, understanding and mastering the Investigational New Drug (IND) application process is essential for pharmaceutical and biotechnology companies.

  This webinar offers a comprehensive guide to navigating the key regulatory requirements under 21 CFR Part 312, ensuring successful IND submissions and ongoing compliance.   Led by regulatory experts Lara Stevanato, PhD, Ergomed’s Associate Director of Regulatory Affairs, and Melanie Pooler, Regulatory Affairs Manager, this session provides actionable insights for navigating the IND process. Whether you’re new to IND submissions or seeking to enhance your knowledge, this webinar equips you with the tools and strategies to succeed.

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.